{
  "@context": "aku-v2",
  "@type": "genetics",
  "@id": "vasc:hht:type2-acvrl1",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:15:00.000Z",
    "updated": "2026-01-07T03:15:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-disorders",
    "type": "genetic-syndrome",
    "difficulty": "advanced",
    "importance": "specialized"
  },
  "content": {
    "title": "Hereditary Hemorrhagic Telangiectasia Type 2 (ACVRL1)",
    "description": "HHT Type 2 caused by mutations in the ACVRL1 gene encoding ALK1",
    "key_concepts": [
      {
        "concept": "Genetic Basis",
        "details": "Autosomal dominant mutations in ACVRL1 gene encoding activin receptor-like kinase 1 (ALK1)"
      },
      {
        "concept": "Hepatic AVM Prevalence",
        "details": "Higher prevalence of hepatic AVMs compared to HHT Type 1"
      },
      {
        "concept": "Clinical Features",
        "details": "Later onset of symptoms, mucocutaneous telangiectasias, hepatic vascular malformations"
      },
      {
        "concept": "Pulmonary AVMs",
        "details": "Lower prevalence of pulmonary AVMs (approximately 20-30%) compared to Type 1"
      }
    ],
    "clinical_significance": "HHT Type 2 requires hepatic screening and monitoring for high-output cardiac failure"
  },
  "relationships": [
    {
      "predicate": "relatedTo",
      "object": "vasc:hht:hepatic-avm"
    }
  ],
  "provenance": {
    "primary_sources": ["Faughnan ME et al. J Med Genet 2011"]
  }
}
